Anti-FA12/ F12/ HAE3 monoclonal antibody
Anti-FA12/ F12/ HAE3 antibody for FACS & in-vivo assay
Go to F12/F12 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-T38509-Ab-1/ GM-Tg-hg-T38509-Ab-2 | Anti-Human F12 monoclonal antibody | Human |
GM-Tg-rg-T38509-Ab-1/ GM-Tg-rg-T38509-Ab-2 | Anti-Rat F12 monoclonal antibody | Rat |
GM-Tg-mg-T38509-Ab-1/ GM-Tg-mg-T38509-Ab-2 | Anti-Mouse F12 monoclonal antibody | Mouse |
GM-Tg-cynog-T38509-Ab-1/ GM-Tg-cynog-T38509-Ab-2 | Anti-Cynomolgus/ Rhesus macaque F12 monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-T38509-Ab-1/ GM-Tg-felg-T38509-Ab-2 | Anti-Feline F12 monoclonal antibody | Feline |
GM-Tg-cang-T38509-Ab-1/ GM-Tg-cang-T38509-Ab-2 | Anti-Canine F12 monoclonal antibody | Canine |
GM-Tg-bovg-T38509-Ab-1/ GM-Tg-bovg-T38509-Ab-2 | Anti-Bovine F12 monoclonal antibody | Bovine |
GM-Tg-equg-T38509-Ab-1/ GM-Tg-equg-T38509-Ab-2 | Anti-Equine F12 monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-T38509-Ab-1/ GM-Tg-hg-T38509-Ab-2; GM-Tg-rg-T38509-Ab-1/ GM-Tg-rg-T38509-Ab-2; GM-Tg-mg-T38509-Ab-1/ GM-Tg-mg-T38509-Ab-2; GM-Tg-cynog-T38509-Ab-1/ GM-Tg-cynog-T38509-Ab-2; GM-Tg-felg-T38509-Ab-1/ GM-Tg-felg-T38509-Ab-2; GM-Tg-cang-T38509-Ab-1/ GM-Tg-cang-T38509-Ab-2; GM-Tg-bovg-T38509-Ab-1/ GM-Tg-bovg-T38509-Ab-2; GM-Tg-equg-T38509-Ab-1/ GM-Tg-equg-T38509-Ab-2 |
Products Name | Anti-F12 monoclonal antibody |
Format | mab |
Target Name | F12 |
Protein Sub-location | Transmembrane Protein |
Category of antibody | FACS/Biofunctional Antibody, Therapeutics Target antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-F12 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Biosimilar | GMP-Bios-ab-233 | Pre-Made Garadacimab biosimilar, Whole mAb, Anti-F12 Antibody: Anti-HAE3/HAEX/HAF therapeutic antibody |
Target Antigen | Products Developing | Multi-species FA12/ F12/ HAE3 VLP (virus-like particle) (Products Developing) |
Target information
Target ID | GM-T38509 |
Target Name | F12 |
Gene ID | 2161,58992,306761,699875,489090,100313488,280789,100068589 |
Gene Symbol and Synonyms | F12,FXII,HAE3,HAEX,HAF |
Uniprot Accession | P00748,D3ZTE0,P98140 |
Uniprot Entry Name | FA12_HUMAN,FA12_RAT,FA12_BOVIN |
Protein Sub-location | Transmembrane Protein |
Category | Therapeutics Target, INN Index |
Disease | N/A |
Gene Ensembl | ENSG00000131187 |
Target Classification | N/A |
The target: F12, gene name: F12, also named as HAE3, HAEX, HAF. This gene encodes coagulation factor XII which circulates in blood as a zymogen. This single chain zymogen is converted to a two-chain serine protease with an heavy chain (alpha-factor XIIa) and a light chain. The heavy chain contains two fibronectin-type domains, two epidermal growth factor (EGF)-like domains, a kringle domain and a proline-rich domain, whereas the light chain contains only a catalytic domain. On activation, further cleavages takes place in the heavy chain, resulting in the production of beta-factor XIIa light chain and the alpha-factor XIIa light chain becomes beta-factor XIIa heavy chain. Prekallikrein is cleaved by factor XII to form kallikrein, which then cleaves factor XII first to alpha-factor XIIa and then to beta-factor XIIa. The active factor XIIa participates in the initiation of blood coagulation, fibrinolysis, and the generation of bradykinin and angiotensin. It activates coagulation factors VII and XI. Defects in this gene do not cause any clinical symptoms and the sole effect is that whole-blood clotting time is prolonged. [provided by RefSeq, Jul 2008].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.